News >

Guiding Treatment Decisions in Newly Diagnosed Metastatic Melanoma

Kristi Rosa
Published: Thursday, Jan 16, 2020

Anna C. Pavlick, DO, professor in the Department of Medicine as well as the Ronald O. Perelman Department of Dermatology at NYU Langone Health Perlmutter Cancer Center, director of High Reliability Organization Initiatives and co-director of the Melanoma Program at NYU Langone Health Perlmutter Cancer Center

Anna C. Pavlick, DO

Despite the approvals of targeted agents and immunotherapy in the treatment paradigm of metastatic melanoma, clinical trials remain the gold standard for patients with newly diagnosed disease, according to Anna C. Pavlick, DO.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication